Clinical Trials Logo

Filter by:
NCT ID: NCT04729374 Recruiting - COVID-19 Clinical Trials

COVID-19 Vaccine Induced Adaptive Immune Responses

Start date: January 27, 2021
Phase:
Study type: Observational

The coronavirus disease 2019 (COVID-19) caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),resulting in more than 82 million confirmed cases and caused around 1.8 million deaths, as of 2 January 2021. The ongoing pandemic still poses unprecedented global threat to public health system worldwide. On December 31, 2020, the joint prevention and control agency of China Council announced that Sinopharm SARS-CoV-2 inactivated vaccine had been conditionally approved by National Medical Products Administration, and the protection rate was 79.34%. So far, more than 198 vaccines were currently in preclinical or clinical development. The investigators aimed to initiate an observational cohort of healthy individuals injected with SARS-CoV-2 Vaccine, which will perform a longitudinal, comprehensive analysis of the SARS-CoV-2 vaccine Induced adaptive immune responses.

NCT ID: NCT04728984 Recruiting - Uremic Pruritus Clinical Trials

A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet

Start date: September 7, 2020
Phase: Phase 3
Study type: Interventional

This is a multisite study to evaluate the efficacy, safety and plasma concentration of Nalfurafine Hydrochloride orally disintegrating tablet in the treatment of refractory pruritus in maintenance hemodialysis patients, and to bridge the efficacy data from Japan

NCT ID: NCT04728893 Recruiting - Clinical trials for Hematologic Malignancies

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Start date: April 5, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).

NCT ID: NCT04728841 Recruiting - Hemophilia A Clinical Trials

Gene Therapy for Chinese Hemophilia A

HA
Start date: March 4, 2021
Phase: N/A
Study type: Interventional

IHBDH-GTHA-2020 is an open- label, non- randomized study to evaluate the safety, tolerability and kinetics of a single intravenous infusion of GS001 in hemophilia A subjects with <1 IU/dl residual FVIII levels.

NCT ID: NCT04728724 Recruiting - Clinical trials for Non-small Cell Lung Cancer Stage III

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

Start date: September 10, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II, non-randomized, open-label, multi-center study to evaluate the efficacy of neoadjuvant Sintilimab (PD-1 antibody) or combined with chemotherapy as first-line treatment in patients with stage III non-small cell lung cancer (NSCLC).

NCT ID: NCT04728568 Recruiting - Clinical trials for Meningioma, Malignant

Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

This research study is studying a drug as a possible treatment for High Grade Meningioma.

NCT ID: NCT04728399 Recruiting - Clinical trials for Overweight or Obesity

Soy Peptide, Conjugated Linoleic Acid, Overweight or Obese, Body Composition

Start date: May 14, 2021
Phase: N/A
Study type: Interventional

Soybean peptides are a mixture of active peptides obtained from the hydrolysis of soybean protein, which have biological activities such as antioxidant, blood pressure lowering, anti-fatigue and lipid lowering, etc. They can regulate food intake, increase satiety, and reduce fat body ratio by reducing cholesterol and triglyceride content and stimulating CCK secretion.Conjugated linoleic acid (CLA) is a set of linoleic acid with conjugated unsaturated double bond, the location and structure of the isomers have been approved by the ministry of health in China as a new resource food , widely used in areas such as health care products, functional foods and food additives, animal experiments showed that it has reduce tumor, atherosclerosis, obesity risk.Therefore, in this study, the effect of conjugated linoleic acid combined with soybean peptide on overweight and obese people was investigated in a randomized controlled manner.

NCT ID: NCT04727580 Recruiting - Clinical trials for Impaired Glucose Tolerance

HSK7653 in Chinese Patients With Impaired Glucose Tolerance

Start date: March 29, 2021
Phase: Phase 2
Study type: Interventional

This study is being done to evaluate the efficacy, safety of HSK7653 in chinese participants with impaired glucose tolerance.

NCT ID: NCT04727177 Recruiting - Clinical trials for Transcranial Magnetic Stimulation

Precision-targeted Transcranial Magnetic Stimulation in the Treatment of Primary Dystonia

Start date: November 1, 2020
Phase: Early Phase 1
Study type: Interventional

In this scheme, TMS treatment of Primary dystonia is planned by precise magnetic resonance positioning.

NCT ID: NCT04727034 Recruiting - Gastric Cancer Clinical Trials

Efficacy and Safety of Remimazolam Tosylate for Sedation in Gastroscopy

Start date: March 2, 2021
Phase: N/A
Study type: Interventional

Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high. Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.